Tubulis’ next-generation antibody-drug conjugate (ADC) has been tied to an overall response rate (ORR) of 59% as the German ...

Europe’s leading cancer conference may be swimming in antibody-drug conjugate data, but AstraZeneca remains convinced that ...

BERLIN -- The antibody-drug conjugate (ADC) trastuzumab deruxtecan (T-DXd, Enhertu) delivered impressive results in different ...

AbbVie has announced new clinical data from its antibody-drug conjugate (ADC) platform, reinforcing its commitment to ...

More than 40,000 Americans die from the respiratory illness each year, and over 1.4 million adults seek care in a hospital.

Medical writing assistance was provided by Yolande Chalmers, EMJ, London, UK. The views and opinions expressed in this ...

R-DXd showed a 50.5% objective response rate in platinum-resistant ovarian cancer, with a 5.6 mg/kg dose deemed optimal for further study. The safety profile was manageable, with 93.5% experiencing ...

Discover the emerging field of AI-based peptide discovery and design – could this signal the beginning of a golden age for ...

Findings show that most pneumococcal serotypes now circulating in Bangladesh are not well covered by the existing PCV-10 vaccine, which has been successfully used in the national Expanded Programme on ...

In the ICARUS-BREAST 01 study, more than half of patients with metastatic breast cancer saw their disease decrease or ...

Michael Ritchie, chief commercial officer at Champions Oncology, explains what makes radiopharmaceuticals unique in the treatment of cancer.

Scientists at National Taiwan University (NTU) have developed a pioneering optical microscopy method that can reconstruct a ...